© 2020 MJH Life Sciences and HCPLive. All rights reserved.
Rheumatoid Arthritis
Denosumab Doses Must Be Delivered On Time for Patients With Osteoporosis
August 04, 2020
Article
It is important for clinicians considering prescribing denosumab treatment to counsel patients before its initiation on the importance of not delaying or discontinuing injections.
Tocilizumab Does Not Meet Primary Endpoint in COVID-19 Phase 3 Trial
July 30, 2020
Article
Findings of the trial on tocilizumab fall short.
Upadacitinib Demonstrates Safety and Efficacy for Atopic Dermatitis
July 21, 2020
Article
Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.
ACR Supports Use of Telemedicine for Rheumatology
July 01, 2020
Article
The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.
Filgotinib Effective for Patients With Rheumatoid Arthritis
June 09, 2020
Article
The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.
Tocilizumab Shows Similar Efficacy to Other Targeted Immune Modulators
June 09, 2020
Article
Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.
Philip Mease, MD: The Relationship Between Psoriatic Arthritis and IBD
June 07, 2020
Article
Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.
Tofacitinib Reduces Psychiatric Disorder Rates in Rheumatoid Arthritis Patients
June 07, 2020
Article
Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.
Serious Infection More Likely in Older Rheumatoid Arthritis Patients
June 07, 2020
Article
A team investigated data from trials of tofacitinib, adalimumab, and placebo.
Upadacitinib Improves Rheumatoid Arthritis Symptoms Over Abatacept
June 06, 2020
Article
The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.